anti-Desmocollin 3 (DSC3) Antibodies

Human Desmocollin 3 (DSC3) interaction partners

1. The Findings of this study imply early alteration of the substantia nigra in XDP mutation carriers prone to develop parkinsonism.

2. Data show that fetal pMSCs (mesenchymal stromal cells) expressing the highest levels of desmoglein 2, desmocollin 3 and plakophilin 2, followed by maternal pMSCs, while bmMSCs expressed the lowest levels.

3. Napsin-A, and Desmocollin-3 were sensitive and specific markers for the diagnosis of AC and SCC, respectively. Both markers allowed classification of 54/60 cases into either AC or SCC.

4. Suggest that Dsc3 can mediate FSH-induced ovarian cancer cell proliferation by activating the EGFR/Akt signaling pathway.

5. data suggests that DNA methylation contributes to down-regulation of DSC3 in prostate cancer, and loss of DSC3 predicts poor clinical outcome.

6. Low expression of DSC 1, 2, and 3 was observed in 55, 54, and 79 % of liver metastases.

7. The data show an important role of physiologically occurring transcript d2-d4 in normal brain function. Interference with this role by DSC3 is a likely pathological mechanism in X-chromosomal dystonia parkinsonism syndrome

8. High expression of desmocollin 1 (DSC1) was observed in 41.6%, DSC2 in 58.0%, DSC3 in 61.4%, E-cadherin in 71.4%, CDX2 in 58.0%, PITX1 in 55.0%, CDK4 in 0.2%, TLE1 in 1.3%, Factor H in 42.5%, and MDM2 in 0.2% of colorectal carcinomas.

9. The p53 target gene desmocollin 3 acts as a novel tumor suppressor through inhibiting EGFR/ERK pathway in human lung cancer.

10. These findings demonstrate that IgG autoantibodies against an additional component of the desmosomes, Dsc3, induce loss of keratinocyte adhesion and thus may contribute to blister formation in pemphigus.

11. Methylation status of DSC3 DNA is a prognostic marker for colorectal cancer. P53 appears to have an important role in regulating DSC3 expression.

12. Autoimmunity to DSC3 in Pemphigus vulgaris.

13. Gene-profiling experiments of breast cancer cells infected with wt p53 revealed both MASPIN and desmocollin 3 (DSC3) to be p53-target genes, even though both genes are silenced in association with aberrant cytosine methylation of their promoters

14. Lss of DSC3 expression is a common event in primary breast tumor specimens, and DSC3 gene silencing in breast tumors is frequently linked to aberrant cytosine methylation and concomitant changes in chromatin structure.

15. Increased Dsc3 protein is associated with colorectal cancer

16. results suggest an abnormal expression of Dsc3, Dsg3, & beta-catenin induced in the progression of oral carcinomas & that Dsc3 expression level might be related to the regulation of beta-catenin in lymph node metastasis and cell proliferation in OSCCs.

17. Desmocollin-3 was expressed in almost half of the undifferentiated large-cell cancers

18. Both the binding of desmocollin 3 (Dsc3) to plakoglobin and Dsc3 phosphorylation are involved in Dsc3 binding to desmoglein 3 (Dsg3) during Ca2+ -induced desmosome assembly.

19. loss of heterophilic Dsc3/Dsg1 binding may contribute to pemphigus skin blistering

20. a human desmocollin-3 (DSC3) nonsense mutation underlies hereditary hypotrichosis and recurrent skin vesicles

Mouse (Murine) Desmocollin 3 (DSC3) interaction partners

1. plakoglobin (Pg) in conjunction with lymphoid enhancer-binding factor 1 (Lef-1) differentially regulates the proximal promoters of Dsc2 and Dsc3

2. hypothesize that DSC3 can contribute to the progression of tumors both by cell adhesion-dependent (skin surface) and likely by cell adhesion-independent (invading tumor cells) mechanisms

3. The function of DSC3 in the development and maintenance of stratified epithelia, in particular the epidermis and hair follicles, was investigated.